Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project Summary/Abstract Shigella species are the cause of bacillary dysentery, a severe diarrheal disease. Shigella are highly infectious, and cause an estimated ~200 million cases and ~200,000 deaths annually, many of which are young children. Because Shigella is a human-specific pathogen, we have—until recently—lacked a genetically tractable and physiologically relevant animal model of shigellosis. As a result, our understanding of shigellosis is based primarily on in vitro studies or non-physiological or non-genetically tractable animal models. Many generally accepted beliefs about Shigella pathogenesis have never been rigorously tested in vivo. In what we consider a major advance for the field, we have developed the first physiological oral infection mouse model for Shigella. Our new model is based on our discovery that a cytosolic innate immune sensor, called the NAIP–NLRC4 inflammasome, is essential for resistance of mice to Shigella. Shigella-infected Nlrc4–/– mice exhibit all the hallmarks of human shigellosis, including weight loss, diarrhea that can be bloody, bacterial replication specifically within intestinal epithelial cells, and a robust neutrophilic inflammatory response. As in humans, shigellosis in Nlrc4–/– mice is self-limiting and resolves spontaneously within a week. Importantly, bacterial virulence determinants known to be essential for virulence in humans are also essential for virulence in our new model. In this proposal, we plan to take advantage of our new Nlrc4–/– mouse model of shigellosis to identify key host and bacterial factors that control pathogenesis. Specifically, our overall hypothesis is that bystander (uninfected) macrophages play a previously unappreciated role in orchestrating immunity to Shigella, and that they do so via two key cytokine axes: a TNF axis that promotes death and expulsion specifically of infected epithelial cells, and an IL-12 axis that promotes IFN gamma production. To test our overall hypothesis, we propose three Specific Aims: (1) Test the hypothesis that macrophages are essential to resist Shigella; (2) Test the hypothesis that TNF protects against Shigella by inducing the selective apoptosis and expulsion of infected intestinal epithelial cells; (3) Test the hypothesis that a macrophage-IL12-lymphocyte- IFN gamma circuit acts to close the epithelial cell niche to Shigella. Our new model of Shigella pathogenesis involves many players—e.g., macrophages, TLRs, IL-12, IFN gamma, TNF—that are not currently believed to play major roles in resistance to Shigella. Thus, we expect that results with our rigorous in vivo experimental model will significantly revise our understanding of this important infectious disease.
Grant Summary
Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $752K for university, nonprofit, healthcare org. Applications are due 2031-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $752K
2031-03-31
- 1Confirm your organization is eligible for Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model: Frequently Asked Questions
Who is eligible for the Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model?
Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model provide?
Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model provides up to $752K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model deadline?
Applications for Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model are due 2031-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model?
To apply for Dissection of Shigella pathogenesis in vivo using a new oral infection mouse model, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.